AU2013202981B2 - Method of weight reduction - Google Patents

Method of weight reduction Download PDF

Info

Publication number
AU2013202981B2
AU2013202981B2 AU2013202981A AU2013202981A AU2013202981B2 AU 2013202981 B2 AU2013202981 B2 AU 2013202981B2 AU 2013202981 A AU2013202981 A AU 2013202981A AU 2013202981 A AU2013202981 A AU 2013202981A AU 2013202981 B2 AU2013202981 B2 AU 2013202981B2
Authority
AU
Australia
Prior art keywords
methazolamide
diabetes
treatment
diabetic agent
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013202981A
Other languages
English (en)
Other versions
AU2013202981A1 (en
Inventor
Guy Krippner
Geoff Nicholson
Ken Walder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Naia Metabolic Inc
Original Assignee
Naia Metabolic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naia Metabolic Inc filed Critical Naia Metabolic Inc
Publication of AU2013202981A1 publication Critical patent/AU2013202981A1/en
Application granted granted Critical
Publication of AU2013202981B2 publication Critical patent/AU2013202981B2/en
Assigned to NAIA Metabolic, Inc. reassignment NAIA Metabolic, Inc. Request for Assignment Assignors: VERVA PHARMACEUTICALS LTD
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2013202981A 2012-05-24 2013-03-15 Method of weight reduction Ceased AU2013202981B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651335P 2012-05-24 2012-05-24
US61/651,335 2012-05-24
PCT/AU2013/000259 WO2013173858A1 (en) 2012-05-24 2013-03-15 A method of weight reduction

Publications (2)

Publication Number Publication Date
AU2013202981A1 AU2013202981A1 (en) 2013-12-12
AU2013202981B2 true AU2013202981B2 (en) 2014-11-13

Family

ID=49622926

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013202981A Ceased AU2013202981B2 (en) 2012-05-24 2013-03-15 Method of weight reduction

Country Status (16)

Country Link
US (2) US20150174108A1 (enExample)
EP (1) EP2854806A4 (enExample)
JP (1) JP6438389B2 (enExample)
KR (1) KR20150023404A (enExample)
CN (1) CN104582701B (enExample)
AU (1) AU2013202981B2 (enExample)
BR (1) BR112014029302A2 (enExample)
CA (1) CA2874512A1 (enExample)
CO (1) CO7160083A2 (enExample)
HK (1) HK1209041A1 (enExample)
MX (1) MX2014014316A (enExample)
NZ (1) NZ702666A (enExample)
RU (1) RU2664442C2 (enExample)
SG (1) SG11201407786XA (enExample)
WO (1) WO2013173858A1 (enExample)
ZA (1) ZA201408703B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2660170T3 (es) 2007-01-25 2018-03-21 NAIA Metabolic, Inc. Sensibilizadores a la insulina y métodos de tratamiento
BR112014029308A2 (pt) * 2012-05-24 2017-06-27 Verva Pharmaceuticals Ltd um método de melhorar a função hepática
US10039752B2 (en) * 2016-07-21 2018-08-07 Cipla Limited Methazolamide for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013800A2 (en) * 2000-08-11 2002-02-21 Einar Stefansson Method for the prevention and treatment of retinopathy
WO2007114948A2 (en) * 2006-04-04 2007-10-11 The Brigham And Women's Hospital, Inc. Methods and compositions for inhibiting cell death
WO2008089521A1 (en) * 2007-01-25 2008-07-31 Verva Pharmaceuticals Ltd Insulin sensitisers and methods of treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2783241A (en) * 1957-02-26 S-acylimino-x-substituted-az-i
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6946243B2 (en) * 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
CA2516142A1 (en) * 2003-03-18 2004-09-30 Novartis Ag Compositions comprising fatty acids and amino acids
KR101167579B1 (ko) * 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
WO2005012243A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
TW201105338A (en) * 2009-07-01 2011-02-16 Kissei Pharmaceutical Medicine derived from a combination of SGLT1-inhibitor and DPP-IV inhibitor
CN103068400A (zh) * 2010-06-25 2013-04-24 阿斯顿大学 具有脂类动员性质的糖蛋白及其治疗用途
JP5722892B2 (ja) * 2010-07-15 2015-05-27 武田薬品工業株式会社 複素環化合物
BR112014029308A2 (pt) * 2012-05-24 2017-06-27 Verva Pharmaceuticals Ltd um método de melhorar a função hepática

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013800A2 (en) * 2000-08-11 2002-02-21 Einar Stefansson Method for the prevention and treatment of retinopathy
WO2007114948A2 (en) * 2006-04-04 2007-10-11 The Brigham And Women's Hospital, Inc. Methods and compositions for inhibiting cell death
WO2008089521A1 (en) * 2007-01-25 2008-07-31 Verva Pharmaceuticals Ltd Insulin sensitisers and methods of treatment

Also Published As

Publication number Publication date
CN104582701A (zh) 2015-04-29
CN104582701B (zh) 2018-01-16
BR112014029302A2 (pt) 2017-06-27
EP2854806A1 (en) 2015-04-08
HK1209041A1 (en) 2016-03-24
WO2013173858A1 (en) 2013-11-28
US20150174108A1 (en) 2015-06-25
CO7160083A2 (es) 2015-01-15
CA2874512A1 (en) 2013-11-28
JP2015520759A (ja) 2015-07-23
ZA201408703B (en) 2018-07-25
AU2013202981A1 (en) 2013-12-12
RU2664442C2 (ru) 2018-08-17
EP2854806A4 (en) 2015-11-18
RU2014150946A (ru) 2016-07-10
JP6438389B2 (ja) 2018-12-12
NZ702666A (en) 2016-08-26
MX2014014316A (es) 2015-07-06
US20180333398A1 (en) 2018-11-22
KR20150023404A (ko) 2015-03-05
SG11201407786XA (en) 2015-03-30

Similar Documents

Publication Publication Date Title
US20250325536A1 (en) Therapeutic uses of glp1r agonists
US20210113500A1 (en) Composition containing glibenclamide
US20180333398A1 (en) Method of weight reduction
WO2007149285A2 (en) Method of improved diuresis in individuals with impaired renal function
US20180333399A1 (en) Method of improving liver function
ITMI20002019A1 (it) Metodo per il trattemento dei disturbi metabolici, in particolare diabete oppure una malattia oppure una condizione associate con il diabete
US7998973B2 (en) Tivozanib and temsirolimus in combination
AU2016206292B2 (en) A method of improving liver function
US20210100872A1 (en) Pharmacological Formulation Comprising Cyclo (HIS-PRO) As Effective Ingredient For Preventing Or Treating Diabetes Mellitus
AU2019361856A1 (en) Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy
JP2017128545A (ja) 併用医薬
KR20050016936A (ko) 당뇨병성 합병증의 예방 또는 진전저지용 의약조성물
WO2004105756A2 (en) Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof
Buttram et al. Toxicological Emergencies

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NAIA METABOLIC, INC.

Free format text: FORMER OWNER(S): VERVA PHARMACEUTICALS LTD

MK14 Patent ceased section 143(a) (annual fees not paid) or expired